Autor(es)Castro Fabiano R,Farias Alessandro S,Proença Patricia L F,de La Hoz Cristiane,Langone Francesco,Oliveira Elaine C,Toyama Marcos H,Marangoni Sergio,Santos Leonilda M B

ResumoBiomedical research in which venom components are being investigated for their potential as novel therapeutic agents has emerged as an interesting option. Crotapotin, which is purified from the venom of the rattlesnake Crotalus durissus terrificus, has been described as an anti-inflammatory agent that acts on the innate arm of the immune response. Here we have demonstrated that intraperitoneal administration of crotapotin significantly reduces the severity of experimental autoimmune neuritis (EAN), an experimental model for Guillain-Barré syndrome. The reduction of the severity of the disease is associated with a reduction in the mononuclear cells infiltrating the sciatic nerve and a significant decrease in the lymphocyte proliferative response to neuritogenic peptide.

Palavras-ChaveDemyelination; T-cell activation; Experimental autoimmune neuritis; Guillain-barré syndrome

ImprentaToxicon, v. 49, n. 3, p. 299-305, 2007

DescritoresGuillain-Barre Syndrome - Cell ; Guillain-Barre Syndrome - Cytopathology ; Guillain-Barre Syndrome - Immune response ; Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Immunology

Data de Publicação:2007